Real-world efficacy and retention of guselkumab in psoriatic arthritis: insights from a 12-month multicenter study
Guselkumab demonstrated significant efficacy in reducing disease activity and a favorable retention rate over 12 months in a real-world PsA cohort. These findings support guselkumab as an effective treatment for PsA, although further prospective studies are needed to confirm long-term safety and efficacy.
Authors
- Stefania Calvisi (ORCID: https://orcid.org/0000-0002-9685-4582)
- Lorenzo Dagna (ORCID: https://orcid.org/0000-0002-7428-315X)
- Oscar Massimiliano Epis (ORCID: https://orcid.org/0000-0002-9986-4030)
- Alessandro Tomelleri (ORCID: https://orcid.org/0000-0002-5440-2078)
- Adriana Cariddi
- Antonella Cappelli (ORCID: https://orcid.org/0000-0003-1776-902X)
- Nicola Boffini (ORCID: https://orcid.org/0000-0002-4416-933X)
- Alberto Batticciotto (ORCID: https://orcid.org/0000-0003-3140-1264)
- Nicola Farina (ORCID: https://orcid.org/0000-0001-7650-2582)
- Elena Baldissera (ORCID: https://orcid.org/0000-0002-9292-3851)
- Antonella Adinolfi (ORCID: https://orcid.org/0000-0002-4034-7186)
- Marco Matucci-Cerinic
Institutions
- Vita-Salute San Raffaele University (IT)
- Ospedale di Circolo e Fondazione Macchi (IT)
- Società Italiana di Reumatologia (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
Publication Details
- Journal
- ARP Rheumatology
- Published
- 2025-09-28
- DOI
- https://doi.org/10.63032/iexq7963
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00